Latest Research/Randomised evidence so far does not show GLP-1 drugs protect thinking and memory
Everyday Care & SafetyMeta-Analysis

Randomised evidence so far does not show GLP-1 drugs protect thinking and memory

Published Oct 9, 2026

Methods

Researchers searched for randomised controlled trials up to 1 January 2026 that tested a GLP-1 receptor agonist against a control and measured cognitive performance in adults with type 2 diabetes or mild cognitive impairment. Five trials covering 13,711 participants were included (average age 64.5, average follow-up 28.4 months). After auditing the source data, four trials supplied analysable results for at least one cognitive domain, and each domain was pooled separately.

Findings

For global cognition, three studies produced an effect size of g = 0.014 (95% CI −0.061 to 0.088) — indistinguishable from no effect, with no heterogeneity between studies. For attention, two studies gave g = 0.072 with a confidence interval far too wide to interpret. Delayed memory, executive function, and verbal function each had only one usable study, so they were reported individually rather than pooled. Removing the single largest trial left an imprecise, non-significant estimate, meaning the pooled result's robustness could not be established.

Caveats & Context

The authors describe their own findings as exploratory and hypothesis-generating, because so few trials supplied compatible data per cognitive domain. In most of these trials cognition was a secondary outcome, not what the study was designed and powered to detect. This is an absence of evidence rather than evidence of harm, and it says nothing either way about the established effects of these drugs on weight and blood glucose.

Read the original paper

Impact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Nutrients · doi.org/10.3390/nu18203312